12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GDC-0068: Phase Ib/II started

Roche's Genentech Inc. unit began an international Phase Ib/II trial of GDC-0068 or GDC-0980 ( RG7422) in 262 CRPC patients previously treated with docetaxel. The open-label Phase Ib portion will determine the recommended Phase II dose of GDC-0068 and GDC-0980 each in combination with abiraterone and prednisone/prednisolone. The double-blind, placebo-controlled Phase II portion will compare...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >